168 related articles for article (PubMed ID: 32474857)
1. Relationship between Methylation of FHIT and CDH13 Gene Promoter Region and Liver Cancer.
Tuoya AD; Wang DX; Xing YS; Liu RJ; Hu YX; Zhang MD; Bai TY; Lv XL; Li J; Chang FH
Curr Med Sci; 2020 Jun; 40(3):502-509. PubMed ID: 32474857
[TBL] [Abstract][Full Text] [Related]
2. Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen R; He G; Gao JX
Int J Clin Exp Pathol; 2010 May; 3(5):482-91. PubMed ID: 20606729
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes.
Bai Y; Shen Y; Yuan Q; Lv C; Xing Q
Med Sci Monit; 2019 Feb; 25():1301-1306. PubMed ID: 30773529
[TBL] [Abstract][Full Text] [Related]
4. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
5. Influence of DNA methyltransferase 3b on FHIT expression and DNA methylation of the FHIT promoter region in hepatoma SMMC-7721 cells.
Wang JX; Zhang YG; Zhao LS
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):273-7. PubMed ID: 19502167
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
[TBL] [Abstract][Full Text] [Related]
7. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma.
Lee EJ; Lee BB; Kim JW; Shim YM; Hoseok I; Han J; Cho EY; Park J; Kim DH
Eur J Cancer; 2006 May; 42(7):972-80. PubMed ID: 16564166
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
11. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.
Verri C; Roz L; Conte D; Liloglou T; Livio A; Vesin A; Fabbri A; Andriani F; Brambilla C; Tavecchio L; Calarco G; Calabrò E; Mancini A; Tosi D; Bossi P; Field JK; Brambilla E; Sozzi G;
Am J Respir Crit Care Med; 2009 Mar; 179(5):396-401. PubMed ID: 19096006
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
14. Methylation status of the fragile histidine triad and E-cadherin genes in plasma of cervical cancer patients.
Ren CC; Miao XH; Yang B; Zhao L; Sun R; Song WQ
Int J Gynecol Cancer; 2006; 16(5):1862-7. PubMed ID: 17009983
[TBL] [Abstract][Full Text] [Related]
15. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
16. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological significance of aberrant methylation of the fragile histidine triad gene in patients with hepatocellular carcinoma].
Sun Y; Geng XP; Zhu LX; Xiong QR; Qian YB; Dong GY; Li XM
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):609-12. PubMed ID: 16784654
[TBL] [Abstract][Full Text] [Related]
18. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
20. [Interaction between abnormal expression of fragile histidine triad and methyl-CpG-binding protein 2 on cervical cancerization].
Yang Q; Li Y; Wang L; Song ZC; Feng MJ; Ding L; Wang JT
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 May; 39(5):689-693. PubMed ID: 29860820
[No Abstract] [Full Text] [Related]
[Next] [New Search]
